Qulipta and Aimovig Comparison

Qulipta®(atogepant)	Aimovig®(erenumab-aooe)
Prescription Only Qulipta is a prescription medication that is used as a preventative treatment for episodic migraines. It is a tablet that is taken once daily. The most common side effects are...	Prescription Only Aimovig is a prescription medication that adults can self-inject once a month under the skin to prevent migraine headaches. The most common side effects are injection site...
Administration
Oral. Learn more.	Subcutaneous . Learn more.
Dosing
10 mg, 30 mg, or 60 mg once daily. Severe Renal Impairment or End-Stage Renal Disease: 10 mg once daily.. Learn more.	70 mg once monthly or 140 mg once monthly (for some patients). Learn more.
Latin Shorthand
10mg qd, 30mg qd or 60mg qd Renal Impairment: 10mg qd. Learn more.	70 mg/mo or 140 mg/mo. Learn more.
Out-Of-Pocket Costs With Copay Card
$0. Learn more.	$5. Learn more.
Annual Cap
$6000. Learn more.	Patient specific maximum benefit.. Learn more.
Assistance Expiration
12 30-day prescription fills. Learn more.	Calendar year. Learn more.
Generics
No lower-cost generic available	No lower-cost generic available
Adverse Reactions
The most common adverse reactions (at least 4% and greater than placebo) are nausea, constipation, and fatigue/somnolence.. Learn more.	The most common adverse reactions in AIMOVIG clinical studies (occurring in at least 3% of treated patients and more often than placebo) are injection site reactions and constipation. . Learn more.
Mechanism of Actions (MoA)
CGRP Antagonists. Learn more.	CGRP Antagonist . Learn more.
Special Populations
Is QULIPTA safe to use during pregnancy? There are no adequate data on the developmental risk associated with the use of QULIPTA in pregnant women. In animal studies, oral administration of atogepant during the period of organogenesis (rats and rabbits) or throughout pregnancy and lactation (rats) resulted in adverse developmental effects (decreased fetal and offspring body weight in rats; increased incidence of fetal structural variations in rabbits) at exposures greater than those used clinically. Women who are pregnant or planning to become pregnant should consult with their healthcare provider to determine the best treatment option for their migraine. Is QULIPTA safe to use during lactation? There are no data on the presence of atogepant in human milk, the effects of atogepant on the breastfed infant, or the effects of atogepant on milk production. In lactating rats, oral dosing with atogepant resulted in levels of atogepant in milk approximately 2-fold higher than that in maternal plasma. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for QULIPTA and any potential adverse effects on the breastfed infant from QULIPTA or from the underlying maternal condition. Is QULIPTA safe to use in pediatric patients? Safety and effectiveness in pediatric patients have not been established. QULIPTA is not recommended for use in pediatric patients. Is QULIPTA safe to use in elderly patients? Population pharmacokinetic modeling suggests no clinically significant pharmacokinetic differences between elderly and younger subjects. Clinical studies of QULIPTA did not include sufficient numbers of patients aged 65 years and over to determine whether they respond differently from younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. Is QULIPTA safe to use in patients with hepatic impairment? No dose adjustment of QULIPTA is recommended for patients with mild or moderate hepatic impairment. Avoid use of QULIPTA in patients with severe hepatic impairment. Is QULIPTA safe to use in patients with renal impairment? The renal route of elimination plays a minor role in the clearance of atogepant. No dose adjustment is recommended for patients with mild or moderate renal impairment.	Is it safe to use AIMOVIG during pregnancy? There are no adequate data on the developmental risk associated with the use of AIMOVIG in pregnant women. No adverse effects on offspring were observed when pregnant monkeys were administered erenumab-aooe throughout gestation. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2%-4% and 15%-20%, respectively. The estimated rate of major birth defects (2.2%-2.9%) and miscarriage (17%) among deliveries to women with migraine are similar to rates reported in women without migraine. Healthcare providers are advised to consider the potential risks and benefits of AIMOVIG for pregnant women. Is there any clinical consideration for women with migraine during pregnancy? Published data have suggested that women with migraine may be at increased risk of preeclampsia and gestational hypertension during pregnancy. What animal data is available for AIMOVIG use during pregnancy? In a study in which female monkeys were administered erenumab-aooe (0 or 50 mg/kg) twice weekly by subcutaneous injection throughout pregnancy (gestation day 20-22 to parturition), no adverse effects on offspring were observed. Serum erenumab-aooe exposures (AUC) in pregnant monkeys were approximately 20 times that in humans at a dose of 140 mg once monthly. Is it safe to use AIMOVIG while breastfeeding? There are no data on the presence of erenumab-aooe in human milk, the effects on the breastfed infant, or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for AIMOVIG and any potential adverse effects on the breastfed infant from AIMOVIG or from the underlying maternal condition. Is AIMOVIG safe for use in pediatric patients? Safety and effectiveness in pediatric patients have not been established. Is AIMOVIG safe for use in geriatric patients? Clinical studies of AIMOVIG did not include sufficient numbers of patients aged 65 and over to determine whether they respond differently from younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.

Qulipta®(atogepant)

Aimovig®(erenumab-aooe)

Prescription Only

Qulipta is a prescription medication that is used as a preventative treatment for episodic migraines. It is a tablet that is taken once daily. The most common side effects are...

Prescription Only

Aimovig is a prescription medication that adults can self-inject once a month under the skin to prevent migraine headaches. The most common side effects are injection site...

Dosage & Administration

Administration

Oral. Learn more.

Subcutaneous . Learn more.

Dosing

10 mg, 30 mg, or 60 mg once daily. Severe Renal Impairment or End-Stage Renal Disease: 10 mg once daily.. Learn more.

70 mg once monthly or 140 mg once monthly (for some patients). Learn more.

Latin Shorthand

10mg qd, 30mg qd or 60mg qd Renal Impairment: 10mg qd. Learn more.

70 mg/mo or 140 mg/mo. Learn more.

Financial Assistance

Out-Of-Pocket Costs With Copay Card

$0. Learn more.

$5. Learn more.

Annual Cap

$6000. Learn more.

Patient specific maximum benefit.. Learn more.

Assistance Expiration

12 30-day prescription fills. Learn more.

Calendar year. Learn more.

Generics

No lower-cost generic available

Physician Advisory

Adverse Reactions

The most common adverse reactions (at least 4% and greater than placebo) are nausea, constipation, and fatigue/somnolence.. Learn more.

The most common adverse reactions in AIMOVIG clinical studies (occurring in at least 3% of treated patients and more often than placebo) are injection site reactions and constipation. . Learn more.

Mechanism of Actions (MoA)

CGRP Antagonists. Learn more.

CGRP Antagonist . Learn more.

Special Populations

Is QULIPTA safe to use during pregnancy?

There are no adequate data on the developmental risk associated with the use of QULIPTA in pregnant women. In animal studies, oral administration of atogepant during the period of organogenesis (rats and rabbits) or throughout pregnancy and lactation (rats) resulted in adverse developmental effects (decreased fetal and offspring body weight in rats; increased incidence of fetal structural variations in rabbits) at exposures greater than those used clinically. Women who are pregnant or planning to become pregnant should consult with their healthcare provider to determine the best treatment option for their migraine.

Is QULIPTA safe to use during lactation?

There are no data on the presence of atogepant in human milk, the effects of atogepant on the breastfed infant, or the effects of atogepant on milk production. In lactating rats, oral dosing with atogepant resulted in levels of atogepant in milk approximately 2-fold higher than that in maternal plasma. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for QULIPTA and any potential adverse effects on the breastfed infant from QULIPTA or from the underlying maternal condition.

Is QULIPTA safe to use in pediatric patients?

Safety and effectiveness in pediatric patients have not been established. QULIPTA is not recommended for use in pediatric patients.

Is QULIPTA safe to use in elderly patients?

Population pharmacokinetic modeling suggests no clinically significant pharmacokinetic differences between elderly and younger subjects. Clinical studies of QULIPTA did not include sufficient numbers of patients aged 65 years and over to determine whether they respond differently from younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.

Is QULIPTA safe to use in patients with hepatic impairment?

No dose adjustment of QULIPTA is recommended for patients with mild or moderate hepatic impairment. Avoid use of QULIPTA in patients with severe hepatic impairment.

Is QULIPTA safe to use in patients with renal impairment?

The renal route of elimination plays a minor role in the clearance of atogepant. No dose adjustment is recommended for patients with mild or moderate renal impairment.

Is it safe to use AIMOVIG during pregnancy?

There are no adequate data on the developmental risk associated with the use of AIMOVIG in pregnant women. No adverse effects on offspring were observed when pregnant monkeys were administered erenumab-aooe throughout gestation. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2%-4% and 15%-20%, respectively. The estimated rate of major birth defects (2.2%-2.9%) and miscarriage (17%) among deliveries to women with migraine are similar to rates reported in women without migraine. Healthcare providers are advised to consider the potential risks and benefits of AIMOVIG for pregnant women.

Is there any clinical consideration for women with migraine during pregnancy?

Published data have suggested that women with migraine may be at increased risk of preeclampsia and gestational hypertension during pregnancy.

What animal data is available for AIMOVIG use during pregnancy?

In a study in which female monkeys were administered erenumab-aooe (0 or 50 mg/kg) twice weekly by subcutaneous injection throughout pregnancy (gestation day 20-22 to parturition), no adverse effects on offspring were observed. Serum erenumab-aooe exposures (AUC) in pregnant monkeys were approximately 20 times that in humans at a dose of 140 mg once monthly.

Is it safe to use AIMOVIG while breastfeeding?

There are no data on the presence of erenumab-aooe in human milk, the effects on the breastfed infant, or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for AIMOVIG and any potential adverse effects on the breastfed infant from AIMOVIG or from the underlying maternal condition.

Is AIMOVIG safe for use in pediatric patients?

Safety and effectiveness in pediatric patients have not been established.

Is AIMOVIG safe for use in geriatric patients?

Clinical studies of AIMOVIG did not include sufficient numbers of patients aged 65 and over to determine whether they respond differently from younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.

Qulipta® Alternatives